GlycoMimetics Inc stock (US38000Q1022): Reverse split and ticker change to CBIO

GlycoMimetics, Inc. (GLYC) executed a 1-for-100 reverse stock split and changed its ticker to CBIO, consolidating shares amid biotech sector pressures.

GlycoMimetics, Inc., a biotechnology firm focused on cancer therapies, implemented a 1-for-100 reverse stock split and transitioned its ticker symbol from GLYC to CBIO. This corporate action, tracked on major trading platforms, aims to meet exchange listing requirements by boosting the per-share price. Shareholders now hold 1 share of CBIO for every 100 prior GLYC shares, according to Robinhood as of 2026.

The reverse split took effect recently, reflecting efforts to maintain Nasdaq compliance amid volatile biotech valuations. GlycoMimetics develops selectin-based therapeutics for blood cancers and solid tumors, with its lead candidate uproleslenligel previously in late-stage trials. Such restructurings are common in clinical-stage biotechs facing share price declines.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GlycoMimetics, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US oncology market
• Key revenue drivers: Clinical-stage drug candidates
• Home exchange/listing venue: Nasdaq (CBIO)
• Trading currency: USD

GlycoMimetics Inc: core business model

GlycoMimetics Inc specializes in carbohydrate mimicry to target selectins, proteins involved in cancer metastasis and inflammation. The company's pipeline centers on inhibitors like uproleslenligel (GMI-1271), designed to disrupt tumor cell migration. Originally listed as GLYC, it now trades as CBIO post-reverse split, enhancing appeal to US institutional investors seeking Nasdaq-compliant biotech plays.

Founded in 2003 and headquartered in Rockville, Maryland, GlycoMimetics has advanced multiple assets through Phase 3 trials, partnering with firms like Pfizer in prior collaborations. Its model relies on milestone payments, grants, and potential royalties, typical for pre-revenue biotechs with high US market exposure via oncology focus.

Main revenue and product drivers for GlycoMimetics Inc

Primary value drivers include uproleslenligel, tested in acute myeloid leukemia (AML) combinations, and GMI-1689 for sickle cell disease. Despite FDA setbacks in 2023, the pipeline targets multi-billion-dollar US markets, per industry reports. No commercial revenue yet; funding stems from equity raises and partnerships.

Conclusion

The ticker change to CBIO and 1-for-100 reverse split mark a pivotal restructuring for GlycoMimetics Inc, aiming to stabilize its Nasdaq listing amid biotech headwinds. With a focus on innovative selectin inhibitors, the firm remains positioned in high-growth US oncology segments. Investors track pipeline progress and funding runway for future developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.